<DOC>
	<DOCNO>NCT01053936</DOCNO>
	<brief_summary>This study assess effect new formulation bardoxolone methyl eGFR Patients Chronic Kidney Disease Type 2 Diabetes .</brief_summary>
	<brief_title>Phase II Pharmacodynamic Trial Determine Effects Bardoxolone Methyl eGFR Patients With Type 2 Diabetes Chronic Kidney Disease</brief_title>
	<detailed_description>Bardoxolone methyl ( RTA 402 ) Antioxidant Inflammation Modulator ( AIM ) undergo clinical test chronic kidney disease ( CKD ) . Bardoxolone methyl AIMs inhibit immune-mediated inflammation restore redox homeostasis inflame tissue induction cytoprotective transcription factor Nrf2 . In diabetic population , adipocytes produce cytokine mobilize free fatty acid induce insulin resistance . Resultant hyperglycemia increase cytokine production induces reactive oxygen nitrogen specie turn induce vascular inflammation endothelial dysfunction . These stimulus cause activation NF-kB , promote inflammation , mesangial cell contraction , mesangial expansion endothelial dysfunction , end result decrease renal function . By induce Nrf2 suppress redox-driven inflammation , hypothesize inflammation resultant adverse renal functional change patient chronic kidney disease result diabetes suppress . In Phase IIa open label study patient CKD type 2 diabetes , treatment bardoxolone methyl 28 day result significant improvement renal function , include increase eGFR , decrease serum creatinine , cystatin C , BUN , phosphorus , uric acid , creatinine clearance , angiotensin II ; improvement glycemic control assessed hemoglobin A1c ; improvement marker endothelial dysfunction systemic inflammation , circulate endothelial cell adiponectin . These data consistent hypothesis bardoxolone methyl improve renal function suppression renovascular oxidative stress inflammation . A new formulation bardoxolone methyl develop , chemical entity manufacture contain amorphous dispersion rather crystalline solid state . The new amorphous dispersion formulation bardoxolone methyl show orally bioavailable non-human primate . The purpose study determine appropriate dose new bardoxolone methyl formulation use future clinical study determine dose response relationship eGFR .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Patients must history type 2 diabetes ; diagnosis type 2 diabetes make &gt; 30 year age ( diabetes develop young age , Cpeptide level may obtain confirm diagnosis ) ; 2 . Patients must least 18 year age ; 3 . The average 2 eGFR value collect screen must within 15 45 mL /min/1.73m2 inclusive . 4 . Patients must receive angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) least 8 week prior screen , dose ACE inhibitor ARB consider appropriate patient , patient stable maintain dose least 8 week prior randomization ( Day 1 ) . No change ACE ARB therapy anticipate planned period study . 5 . Male female patient must agree use effective contraception entire study period least 2 month last dose study drug , unless documentation infertility exist 6 . Women childbearing potential must negative serum pregnancy test result screen confirm negative urine pregnancy test result prior administration first dose study medication ; 7 . Patient willing able cooperate aspect protocol ; 8 . Patient willing able give write informed consent study participation 1 . Any patient Type 1 ( insulindependent ; juvenile onset ) diabetes ; history diabetic ketoacidosis ; 2 . Any patient know nondiabetic renal disease , family history hereditary form kidney disease , patient history renal transplant . 3 . Any patient clinical renal biopsy evidence nondiabetic renal disease nephrosclerosis ; 4 . Any patient blood pressure ( BP ) unable control systolic pressure ( SeSBP ) &lt; 160 mmHg diastolic pressure ( SeDBP ) &lt; 90 mmHg . BP determine average 3 reading , take seat least 5minutes . BP must within range take 2 separate timepoints least 4 day apart screen period ; 5 . Any patient Hemoglobin A1c level &gt; 10 % collected screening ; 6 . Any patient cardiovascular disease follow : 1 . Unstable angina pectoris within 3 month study randomization ; 2 . Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 3 month study randomization ; 3 . Transient ischemic attack within 3 month study randomization ; 4 . Cerebrovascular accident within 3 month study randomization ; 5 . Obstructive valvular heart disease hypertrophic cardiomyopathy ; 6 . 2nd degree 3rd degree atrioventricular block successfully treat pacemaker ; 7 . Current diagnosis Class III IV congestive heart failure ; 7 . Any patient QTc Fredericia interval &gt; 450 millisecond determined average value report central reader 3 ECGs take Screening Visit . 8 . Any patient need chronic ( &gt; 2 week ) immunosuppressive therapy , include corticosteroid ( exclude intraarticular injection inhale nasal steroid ) within 3 month prior randomization ; 9 . Any patient require occasional ( twice weekly ) use nonsteroidal antiinflammatory agent ( NSAIDS ) ; 10 . Any patient require change dose adjustment follow medication : ACE inhibitor ARBs within 8 week ; antihypertensive , antidiabetic medication within 6 week prior study randomization ; 11 . Any patient unable unwilling discontinue follow medication throughout study period : Niacin® ( nicotinic acid ) , Niaspan® ( nicotinic acid ) , Niacor® ( nicotinic acid ) , Nicolar® ( nicotinic acid ) , Nicobid® ( nicotinic acid ) , Nydrazid® ( isoniazid ) , Dantrium® ( dantrolene ) , Normodyne® ( labetalol ) , Trandate® ( labetalol ) , Cylert® ( pemoline ) , Tradon® ( pemoline ) , PemADD® ( pemoline ) , Felbatol® ( felbamate ) , Zyflo® ( zileuton ) , Tasmar® ( tolcapone ) , Tricor® ( fenofibrate ) , Antaram® ( fenofibrate ) , Triglide® ( fenofibrate ) , Lofibra® ( fenofibrate ) , Lipidil Micro® ( fenofibrate ) , Lipidil Supra® ( fenofibrate ) ; include fenofibrate derivative e.g . Lopid® ( gemfibrozil ) AtromidS® ( clofibrate ) . Patient must discontinue aforementioned medication minimum two week prior randomization . Patients may continue use multivitamin ( e.g. , Centrum ) ® , maximum total daily consumption &lt; = 50 mg nicotinic acid ( Niacin® ) ; 12 . Any patient evidence hepatic biliary dysfunction include level total bilirubin &gt; 1.0 mg/dL ( &gt; 17 micromole/L ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; upper limit normal ( ULN ) , alkaline phosphatase &gt; 2.0 time ULN ANY screen laboratory test result ; 13 . If patient provide history hepatitis B C normal liver enzyme level , investigator perform serologic hepatitis screen call Medical Monitor discuss patient eligibility . Patients history hepatitis A resolve demonstrate liver enzyme level elevation eligible protocol randomization ; 14 . Any female patient pregnant , nurse planning pregnancy ; 15 . Any patient know hypersensitivity component study drug ; 16 . Any patient undergone diagnostic intervention procedure require contrast agent within last 30 day prior study randomization ; 17 . Patient current history drug alcohol abuse per Investigator 's assessment ; 18 . Any patient history neoplastic disease ( except basal squamous cell carcinoma skin ) within 5 year prior study randomization ; 19 . Any patient dialysis within 3 month randomization and/or maintain stable level kidney function within 3 month randomization per Investigator assessment ; 20 . Any patient concurrent clinical condition judgment investigator could either potentially pose health risk patient involve study could potentially influence study outcome ; 21 . Any patient participate another clinical study involve investigational market product within 30 day prior randomization would concomitantly participate study , patient receive bardoxolone methyl form ; 22 . Any patient unable communicate cooperate Investigator due language problem , poor mental development , impaired cerebral function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>